NCT03816332 2025-10-09
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center